Active surveillance is part of the therapeutic possibilities of localized prostate cancer at low-risk of progression.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Patients are eligible for this support modality if they meet specific criteria of indolent cancer. In this population, active surveillance will consist of a regular physical examination, monitoring of PSA and repeating prostate biopsies and/or MRI to assess the absence of evolution of the diagnosed prostate cancer. I
n case of modification or worsening of the monitoring criteria in favor of evolution of the cancer, the patient will be offered a deferred active treatment such as radical prostatectomy, external beam radiotherapy, brachytherapy or focal treatment.
For patients still meeting the eligibility criteria, active surveillance avoids an unnecessary treatment potentially responsible of genitourinary adverse events.
Prog Urol. 2015 Jul 13. pii: S1166-7087(15)00201-8. doi: 10.1016/j.purol.2015.06.010. [Epub ahead of print]
[Article in French]
Service d'urologie, hôpital européen Georges-Pompidou, 20-40, rue Leblanc, 75015 Paris, France.